Kite Pharma, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (52)

View All

Latest Posts

About This Stock More About This Stock
Gilead Sciences To Acquire Immunomedics
Article By: Business Wire
Sunday, September 13, 2020 3:51 PM EDT
Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share. The transaction values Immunomedics at approximately $21 billion.
In this article: IMMU, GILD Also: KITE
Read
Clovis: Evaluating The Prospects Of A Possible Acquisition
Article By: Dr. Hung Tran
Thursday, January 16, 2020 9:27 AM EDT
Riding robust data, Rubraca is most likely to gain approval for resistant prostate cancer having the BRCA mutation. Here I present a scientific analysis to merger and acquisition to give you more insight into Clovis.
In this article: CLVS Also: AZN, BMY, GSK, MRK, RHHBY, JUNO, KITE, CORI, TSRO
Read
4 Biotech Stocks That Show Promise On Sustainable Growth
Article By: Zacks Investment Research
Friday, September 15, 2017 7:20 AM EDT
Within the Medical sector, biotech stocks have performed well in the first half of the year, despite challenges like rising competition, pipeline setbacks, slowdown in growth of mature products and generic competition for certain key drugs.
In this article: SGMO, CORT, HSKA, HLUYY Also: LLY, ALXN, GILD, KITE
Read
Biotech Momentum Eases: September Is A Bit Sluggish
Article By: Rod Raynovich
Thursday, September 14, 2017 6:08 PM EDT
Risks for biotech stocks and the healthcare sector, in general, are with Congress: drug pricing debate and/or lack of progress on tax reform.
In this article: BLUE, XLV, IBB, ABBV, XBI, HALO, PFE, CLLS, ARRY, RXDX, KITE, AGIO, CLVS, EXEL, INCY, JUNO, TSRO, PBYI
Read
5 Top-Ranked Biotech Stocks To Buy Right Now
Article By: Arpita Dutt
Monday, September 11, 2017 1:09 PM EDT
Picking biotech stocks can be a bit tricky given the “high risk - high returns” nature of the industry. Moreover, the estimate revision trend for the sector is not very encouraging.
In this article: REGN, ALXN, LGND, SGMO, FATE Also: KITE, GILD
Read
All Posts

Latest Tweets for $KITE

No tweets yet!

PARTNER HEADLINES

$KITE

Comments Status Updates
Gilead Sciences Takes First Step Towards Higher Valuation Multiple
Moon Kil Woong • 8/28/2017 9:38:10 PM

I tend to look down on companies that depend on buying up others to fuel their research and growth, especially at high valuations when their own stock has a low valuation. I'd be somewhat neutral on this buyout. The real winner is $KITE and their competitors, not #Gilead.

Biotech Buzz Is Broken
Alpha Stockman • 4/29/2015 7:09:10 PM

$KITE opened pretty good, $JUNO needs a bounce

1 to 2 of 2 comments